Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (NCT02099175) | Clinical Trial Compass
UnknownPhase 2
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Italy41 participantsStarted 2013-11
Plain-language summary
Sinonasal tumors are rare diseases, so no standard treatment for such aggressive tumors has been reported, given rarity, absence of prospective study and heterogeneity of histologies and stages of diseases. This study proposes innovative integration of multiple modality of treatment depending by histology, molecular profile and response to induction CT. Moreover, such strategies allows the use of latest technology with greater biological effectiveness and reduction of toxicities.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed and dated IEC-approved Informed Consent
✓. Diagnosis of sinonasal tumor with the following histotypes:
✓. AJCC stage II-III-IVa with the exception of Esthesioneuroblastoma and Intestinal Type Ethmoid Adenocarcinoma where stage III-IV only will be included.
✓. Resectable disease.
✓. ECOG performance status 0-2.
✓. Adequate bone marrow, renal and hepatic functionality, defined as haemoglobin \>10 g/dL, neutrophils \>1500/mmc, platelets \> 100.000/mmc, creatinine value ≤ 1.5 x ULN or calculated creatinine clearance (by Cockcroft and Gault's formula) \> 60 mL/min, transaminases values \< 1.5 times over the upper normal limit (ULN).
✓. Polychemotherapy treatment clinical feasibility as per Investigator's Judgment.
✓. Male or female patients ≥ 18 years of age.
Exclusion criteria
✕. Previous radiotherapy or chemotherapy for head and neck district tumors (surgical treatment relapses are admitted).
✕. Metastatic disease.
✕. Cardiac, pulmonary, infective, neurological disease or any other medical condition that could interfere with treatment.
✕. Unable and unwilling to comply with scheduled visits, therapy plans, and laboratory tests required in this protocol.
What they're measuring
1
Progression Free Survival (PFS)
Timeframe: PFS will be assessed at 5 years.
Trial details
NCT IDNCT02099175
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
✕. Previous diagnosis of other malignant neoplasm in the last 3 years (in situ cervical cancer or completely excised basocellular/squamocellular skin cancer are always admitted).
✕. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
✕. Current or concomitant enrollment in another therapeutic clinical trial.